Trident Lifeline Ltd
Incorporated in 2014, Trident Lifeline Ltd manufactures and sells pharmaceuticals
products[1]
- Market Cap ₹ 325 Cr.
- Current Price ₹ 273
- High / Low ₹ 328 / 230
- Stock P/E 15.5
- Book Value ₹ 84.1
- Dividend Yield 0.00 %
- ROCE 20.6 %
- ROE 23.1 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
- Company has high debtors of 208 days.
- Promoter holding has decreased over last 3 years: -7.45%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|
| 22 | 32 | 45 | 87 | 129 | 141 | |
| 19 | 25 | 36 | 72 | 101 | 109 | |
| Operating Profit | 3 | 6 | 8 | 15 | 28 | 31 |
| OPM % | 12% | 20% | 18% | 17% | 22% | 22% |
| 1 | 1 | 2 | 8 | 9 | 8 | |
| Interest | 0 | 0 | 1 | 4 | 4 | 4 |
| Depreciation | 0 | 0 | 1 | 5 | 6 | 6 |
| Profit before tax | 3 | 7 | 9 | 14 | 27 | 30 |
| Tax % | -32% | 8% | 32% | 23% | 29% | |
| 4 | 6 | 6 | 10 | 19 | 22 | |
| EPS in Rs | 4.94 | 5.24 | 5.51 | 10.22 | 15.96 | 17.73 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 60% |
| TTM: | 66% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 47% |
| TTM: | 31% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 9% |
| 1 Year: | 3% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 20% |
| Last Year: | 23% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 8 | 12 | 12 | 12 | 12 |
| Reserves | -3 | 34 | 41 | 53 | 88 |
| 2 | 8 | 18 | 54 | 73 | |
| 7 | 9 | 16 | 37 | 63 | |
| Total Liabilities | 14 | 63 | 87 | 156 | 237 |
| 1 | 3 | 21 | 44 | 61 | |
| CWIP | 0 | 5 | 4 | 2 | 18 |
| Investments | 0 | 3 | 4 | 11 | 8 |
| 12 | 51 | 58 | 99 | 150 | |
| Total Assets | 14 | 63 | 87 | 156 | 237 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| -0 | -19 | 2 | -10 | 5 | |
| -0 | -10 | -20 | -14 | -37 | |
| 1 | 42 | 11 | 20 | 34 | |
| Net Cash Flow | 0 | 14 | -7 | -4 | 2 |
| Free Cash Flow | -1 | -26 | -16 | -21 | -29 |
| CFO/OP | -8% | -294% | 56% | -38% | 45% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 83 | 139 | 110 | 116 | 208 |
| Inventory Days | 95 | 129 | 156 | 226 | 174 |
| Days Payable | 134 | 87 | 94 | 119 | 183 |
| Cash Conversion Cycle | 44 | 182 | 173 | 224 | 199 |
| Working Capital Days | 49 | 275 | 205 | 144 | 134 |
| ROCE % | 23% | 15% | 18% | 21% |
Insights
In beta| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Africa Revenue Share % ・Standalone data |
|
||||||
| Export Revenue Share (Direct + Merchant Exports) % ・Standalone data |
|||||||
| Tablet Revenue Share % ・Standalone data |
|||||||
| Products in Portfolio count ・Standalone data |
|||||||
| Consolidated Manufacturing Capacity - Tablets Million per Month ・Standalone data |
|||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement Under Regulation 30(LODR)-Trident Lifeline Limited Featured In India Pharma Outlook Magazine
- Trident Lifeline featured in India Pharma Outlook magazine on August 22, 2026.
-
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirement) Regulations, 2015- Intimation Of Award
- Trident Lifeline won Fastest Growing SMEs award at Gujarat Top 50 SME Awards on August 20, 2026.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- Company held analyst/institutional investor meetings in Surat on August 20, 2026.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- Pursuant to the requirements of Regulation 30 of the Securities Exchange Board of India (Listing obligation and Disclosure Requirements) Regulations, 2015, we would like to …
-
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirement) Regulations, 2015- Intimation Of Award
- Trident Lifeline selected for ‘Fastest Growing SMEs’ award; presentation on 20 August 2026 in Ahmedabad.
Concalls
-
Aug 2026TranscriptAI SummaryPPT
-
May 2026TranscriptAI SummaryPPT
-
Jan 2026TranscriptAI SummaryPPT
-
Nov 2025TranscriptAI SummaryPPT
-
Jul 2025TranscriptAI SummaryPPT
-
Oct 2024TranscriptAI SummaryPPT
-
Jul 2024TranscriptAI SummaryPPT
-
May 2024TranscriptAI SummaryPPT
-
Nov 2023TranscriptAI SummaryPPT
-
Jul 2023TranscriptAI SummaryPPT
-
May 2023TranscriptAI SummaryPPT
-
Jan 2023TranscriptAI SummaryPPT
Business Overview:[1]
TLL is a Surat-based pharmaceutical and healthcare-products company. It began as an export-oriented formulations company using third-party and loan-licence manufacturing. It is now evolving into a vertically integrated healthcare-manufacturing platform through its own and subsidiary facilities.